image
Healthcare - Drug Manufacturers - General - NYSE - US
$ 56.22
-3.9 %
$ 114 B
Market Cap
-15.7
P/E
1. INTRINSIC VALUE

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma.[ Read More ]

The intrinsic value of one BMY stock under the base case scenario is HIDDEN Compared to the current market price of 56.2 USD, Bristol-Myers Squibb Company is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BMY

image
FINANCIALS
45 B REVENUE
-2.50%
16.6 B OPERATING INCOME
60.71%
8.04 B NET INCOME
26.71%
13.9 B OPERATING CASH FLOW
6.08%
-2.3 B INVESTING CASH FLOW
-116.10%
-9.42 B FINANCING CASH FLOW
44.49%
11.9 B REVENUE
-2.53%
4.58 B OPERATING INCOME
77.17%
1.22 B NET INCOME
-27.44%
5.59 B OPERATING CASH FLOW
140.37%
-219 M INVESTING CASH FLOW
83.40%
-3.85 B FINANCING CASH FLOW
4.25%
Balance Sheet Decomposition Bristol-Myers Squibb Company
image
Current Assets 31.8 B
Cash & Short-Term Investments 12.3 B
Receivables 15.3 B
Other Current Assets 4.23 B
Non-Current Assets 63.4 B
Long-Term Investments 2.5 B
PP&E 8.04 B
Other Non-Current Assets 52.9 B
Current Liabilities 22.3 B
Accounts Payable 3.26 B
Short-Term Debt 3.28 B
Other Current Liabilities 15.7 B
Non-Current Liabilities 43.4 B
Long-Term Debt 38.2 B
Other Non-Current Liabilities 5.23 B
EFFICIENCY
Earnings Waterfall Bristol-Myers Squibb Company
image
Revenue 45 B
Cost Of Revenue 10.7 B
Gross Profit 34.3 B
Operating Expenses 34.3 B
Operating Income 16.6 B
Other Expenses 8.56 B
Net Income 8.04 B
RATIOS
76.24% GROSS MARGIN
76.24%
36.88% OPERATING MARGIN
36.88%
17.83% NET MARGIN
17.83%
27.27% ROE
27.27%
8.43% ROA
8.43%
22.85% ROIC
22.85%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bristol-Myers Squibb Company
image
Net Income 8.04 B
Depreciation & Amortization 9.76 B
Capital Expenditures -1.21 B
Stock-Based Compensation 518 M
Change in Working Capital -1.91 B
Others 378 M
Free Cash Flow 12.7 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bristol-Myers Squibb Company
image
Wall Street analysts predict an average 1-year price target for BMY of $54.3 , with forecasts ranging from a low of $41 to a high of $67 .
BMY Lowest Price Target Wall Street Target
41 USD -27.07%
BMY Average Price Target Wall Street Target
54.3 USD -3.36%
BMY Highest Price Target Wall Street Target
67 USD 19.17%
4. DIVIDEND ANALYSIS
1.16% DIVIDEND YIELD
0.6 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Bristol-Myers Squibb Company
image
Sold
0-3 MONTHS
38.9 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
100 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
673 K USD 2
9-12 MONTHS
Date Value Insider Amount Avg Price
1 week ago
Nov 04, 2024
Sell 38.9 K USD
Holzer Phil M
SVP and Controller
- 700
55.615 USD
2 weeks ago
Nov 01, 2024
Bought 100 K USD
Hirawat Samit
EVP,Chief Med.Offr.,Drug Dev.
+ 1830
54.675 USD
11 months ago
Dec 05, 2023
Bought 99.6 K USD
BOERNER CHRISTOPHER S.
Chief Executive Officer
+ 2000
49.78 USD
11 months ago
Nov 28, 2023
Bought 150 K USD
BOERNER CHRISTOPHER S.
Chief Executive Officer
+ 3071
48.86 USD
11 months ago
Nov 20, 2023
Bought 423 K USD
Samuels Theodore R. II
Director
+ 8500
49.81 USD
1 year ago
Aug 24, 2023
Sell 1.1 M USD
Powell Ann
EVP, Chief Human Resources
- 17986
61.25 USD
1 year ago
Aug 03, 2023
Sell 44.8 K USD
Plenge Robert M
EVP, Chief Research Officer
- 732
61.14 USD
1 year ago
May 03, 2023
Sell 3.38 M USD
VESSEY RUPERT
EVP & President, Research
- 50385
67.06 USD
1 year ago
Feb 06, 2023
Sell 17.9 M USD
Caforio Giovanni
Board Chair and CEO
- 240000
74.65 USD
1 year ago
Feb 06, 2023
Sell 835 K USD
Powell Ann
EVP, Chief Human Resources
- 11183
74.69 USD
2 years ago
Nov 09, 2022
Sell 1.31 M USD
Powell Ann
EVP, Chief Human Resources
- 16250
80.45 USD
2 years ago
Nov 07, 2022
Sell 3.62 M USD
VESSEY RUPERT
EVP, Research & Early Dev.
- 45910
78.88 USD
2 years ago
Sep 20, 2022
Sell 1.74 M USD
Caforio Giovanni
Board Chair and CEO
- 25000
69.71 USD
2 years ago
Sep 15, 2022
Sell 3.59 M USD
Caforio Giovanni
Board Chair and CEO
- 50000
71.84 USD
2 years ago
Sep 13, 2022
Sell 7.41 M USD
Elkins David V
EVP, Chief Financial Officer
- 103951
71.29 USD
2 years ago
Sep 13, 2022
Sell 2.14 M USD
Elkins David V
EVP, Chief Financial Officer
- 30000
71.35 USD
2 years ago
Sep 14, 2022
Sell 1.77 M USD
Powell Ann
EVP, Chief Human Resources
- 25000
70.75 USD
2 years ago
Jun 13, 2022
Sell 2.22 M USD
Caforio Giovanni
Board Chair and CEO
- 30000
74.04 USD
2 years ago
Jun 06, 2022
Sell 4.87 M USD
LEUNG SANDRA
EVP, General Counsel
- 65000
74.89 USD
7. News
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® plus Yervoy® for the First-Line Treatment of Adult Patients with Microsatellite. businesswire.com - 2 days ago
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARE--Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of advanced ROS1-Positive Non-Small Cell Lung Cancer. businesswire.com - 2 days ago
Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months after a federal judge abruptly dismissed an earlier version of the case. reuters.com - 2 days ago
2 Beaten-Down Dividend Stocks to Buy and Hold They're down, but they aren't out, at least not in the eyes of patient investors. fool.com - 3 days ago
3 Stocks Seeing Insider Buys: CNC, PFE, BMY Investors can see insider buys as an overall net positive concerning the longer-term outlook for a stock. zacks.com - 4 days ago
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock Leerink Partners has upgraded Bristol-Myers Squibb & Co BMY, stating that the company enters a catalyst-rich period in 2025-2027 beyond Cobenfy (a schizophrenia drug) and milvexian (anticoagulant). benzinga.com - 4 days ago
AbbVie's loss is Bristol Myers Squibb's gain - analyst Recent trial failures over at pharma giant AbbVie Inc have created a window of opportunity for competitor Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP), is analysts at UBS are to be believed. AbbVie stock took a $38 billion hit on Monday after the company revealed that Phase 2 trials of its emraclidine schizophrenia treatment have failed to meet their primary endpoint objectives. proactiveinvestors.com - 4 days ago
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say AbbVie's “pain” is Bristol Myers Squibb's “gain,” says Truist Securities analyst Srikripa Devarakonda. marketwatch.com - 5 days ago
Buy, Sell, Or Hold BMY Stock? Bristol Myers Squibb stock (NYSE: BMY) was up 10% on Monday, November 11, after its peer AbbVie (NYSE; ABBV) announced that two of its mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their primary goal. [1] Emraclidine was developed by Cerevel Therapeutics, which AbbVie acquired for around $9 billion earlier this year. forbes.com - 5 days ago
Bristol-Myers Squibb Company (BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference (Transcript) Bristol-Myers Squibb Company (NYSE:BMY ) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Company Participants Samit Hirawat - EVP, Chief Medical Officer, Global Drug Development Robert Plenge - EVP, Chief Research Officer Conference Call Participants Seamus Fernandez - Guggenheim Seamus Fernandez Okay. So, in the interest of staying on time here, really pleased to have Bristol Myers Squibb joining us. seekingalpha.com - 5 days ago
Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell? BMY has been having a good run for the past three months. The stock recently touched a 52-week high. zacks.com - 5 days ago
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug. marketwatch.com - 5 days ago
8. Profile Summary

Bristol-Myers Squibb Company BMY

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 114 B
Dividend Yield 1.16%
Description Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Contact 430 East 29th Street, New York, NY, 10016 https://www.bms.com
IPO Date June 1, 1972
Employees 34100
Officers Ms. Sandra Leung Esq. Executive Vice President & General Counsel Mr. Samit Hirawat M.D. Executive Vice President, Chief Medical Officer & Head of Development Ms. Kimberly M. Jablonski Chief Compliance & Ethics Officer Ms. Ahn Amanda Poole Executive Vice President & Chief Human Resources Officer Mr. Adam Lenkowsky Executive Vice President, Chief Commercialization Officer & Head of U.S. Oncology Dr. Joseph J. Eiden Jr. Head of Medical Affairs Mr. David V. Elkins Executive Vice President & Chief Financial Officer Dr. Christopher S. Boerner Ph.D. Chief Executive Officer & Chairman Mr. Greg Meyers Executive Vice President and Chief Digital & Technology Officer Mr. Timothy Power Vice President & Head of Investor Relations